DNA encoding a single mycobacterial antigen protects against leprosy infection
Related Experiment Video
Updated: Aug 19, 2026
DNA Fingerprinting of Mycobacterium leprae Strains Using Variable Number Tandem Repeat (VNTR) - Fragment Length Analysis (FLA)
Published on: July 15, 2011
E Martin1, P W Roche, J A Triccas
1Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, NSW 2042, Newtown, Australia.
Abstract:
The continuing incidence of leprosy infection around the world and the inability of Mycobacterium bovis bacille Calmette-Guérin (BCG) to protect certain populations clearly indicates that an improved vaccine against leprosy is needed. The immuno dominant 35 kDa protein, shared by Mycobacterium leprae and Mycobacterium avium, but not Mycobacterium tuberculosis or BCG, is recognised by >90% of leprosy patients, making it an ideal candidate antigen for a subunit vaccine. Immunization of outbred Swiss Albino mice with a DNA-35 vaccine stimulated specific T cell activation and IFN-gamma production. DNA-35 immunization induced significant levels of protection against M. leprae footpad infection, comparable to that produced by BCG. Therefore, DNA immunization with the 35 kDa antigen is effective against M. leprae infection and genetic immunization with a combination of antigens holds the potential for an improved vaccine against leprosy.
Insights
An improved leprosy vaccine is needed. DNA immunization using a 35 kDa antigen from Mycobacterium leprae shows promise, inducing protection comparable to BCG in mice.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Leprosy remains a global health concern, with current vaccines like BCG offering incomplete protection.
- A need exists for a more effective leprosy vaccine to combat ongoing infections.
Purpose of the Study:
- To evaluate the efficacy of a DNA vaccine encoding the 35 kDa antigen of Mycobacterium leprae as a potential leprosy vaccine.
- To assess the immune response and protective capabilities of the DNA-35 vaccine in a mouse model.
Main Methods:
- Developed a DNA vaccine (DNA-35) encoding the immunodominant 35 kDa protein shared by M. leprae and M. avium.
- Immunized outbred Swiss Albino mice with the DNA-35 vaccine.
- Assessed T cell activation, IFN-gamma production, and protection against M. leprae footpad infection.
Main Results:
- DNA-35 immunization stimulated specific T cell activation and interferon-gamma (IFN-gamma) production.
- The vaccine induced significant protection against M. leprae infection in mice.
- Protection levels were comparable to those achieved with the BCG vaccine.
Conclusions:
- DNA immunization with the 35 kDa antigen is an effective strategy against M. leprae infection.
- Genetic immunization using combinations of antigens holds potential for developing improved leprosy vaccines.
Related Concept Videos
01:28Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...